TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00147745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam 3.8g for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colesevelam matching placebo
Description: Colesevelam matching placebo for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (Lantus)
Description: Insulin glargine for 12 weeks
Study: NCT03966014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EM-amoxicillin 3 x 10 days
Description: Patients will receive amoxicillin 500 milligram tid for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EM-amoxicillin 3 x 14 days
Description: Patients will receive amoxicillin 500 milligram tid for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EM-amoxicillin 2 x 14 days
Description: Patients will receive amoxicillin 500 milligram bid for 14 days

Intervention type: OTHER
Group type: OTHER
Intervention: Controls
Description: No intervention.
Study: NCT01901302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5945

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05682040

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Bedside Compression Ultrasonography
Description: Point of Care Ultrasound (Bedside Compression Ultrasonography) vs formal lower extremity Doppler
Study: NCT04639076

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss Program
Description: The BWL group will receive a standard weight loss intervention based on the evidence-based interventions currently being recommended for clinical practice, with general recommendations for caloric reductions based on starting weight and progressive weekly increases of physical activity (PA). Supporting behavioral lessons based on materials used in the Diabetes Prevention Program (DPP) will also be delivered. The weight loss 'prescription' will remain consistent throughout the 3 month trial. Participants will receive digital tools including a study smart phone app that incorporates diet self-monitoring, tracking of behavioral goals, behavioral lessons and resources, and integration of data from a study-provided Wi-Fi enabled scale and physical activity tracker.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Behavioral Weight Loss Program
Description: The PBWL group will receive a calorie goal based on measured resting energy expenditure and baseline PA. In Weeks 1-4, participants will be randomly assigned to test patterns that manipulate diet composition (low-fat or low-carbohydrate), meal frequency (3 or 5-6 meals/day), and PA goals (weekly minutes or daily minutes goals). Following this period, the optimal combination will be identified by the participant and interventionist, based on weight loss, blood glucose, hunger and ability to adhere to the prescription. This group will receive the same supporting behavioral lessons as the BWL group along with additional resources specific to their personalized prescription. The weight loss 'prescription' will vary across the 3-month trial based on response to treatment. Participants will receive the same digital tools as the BWL group with resources specific to following the prescription they are following during any given program week.
Study: NCT01757171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 20mg IV over 1 hour every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 20mg IV over 1 hour every 3 weeks
Study: NCT03151161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib,Pemetrexed,Carboplatin
Description: Pemetrexed (500mg/m2) + Carboplatin (AUC=5), every 3 weeks, maximum 4 cycles; icotinib 125mg, three times a day, d2-15 in each cycle, and icotinib 125mg,three times a day, since the last cycle until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icotinib
Description: Single drug: Icotinib 125mg, three times a day, continuous until disease progression.
Study: NCT00103116

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell cancer vaccine
Description: Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.~Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part.
Study: NCT02498418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Tablets, generic formulation of the brand product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xifaxan®
Description: Tablets, brand product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo tablets in the same image of the generic rifaximin. Has no active ingredient.
Study: NCT01026103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tri Staple Technology stapler
Description: This is a single arm study.
Study: NCT04494152

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography
Description: Standard Point-of-Care echocardiographic examination in the intensive care unit.
Study: NCT00567242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word-finding with intention component
Description: Word-finding trials (picture-naming) with intention manipulation (initiating word-finding trials with a complex left-hand movement). 8 (or more) baseline sessions over 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Word-finding with no intention component
Description: Word-finding trials with no intention manipulation. 8 (or more) baseline sessions in 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
Study: NCT03348254

Intervention type: DRUG
Intervention: Single shot antibiotic prophylaxis
Description: single shot preoperative antibiotic prophylaxis

Intervention type: DRUG
Intervention: Multiple shot antibiotic prophylaxis
Description: Multiple shot perioperative antibiotic prophylaxis
Study: NCT03433742

Intervention type: OTHER
Group type: OTHER
Intervention: Blood levels drawn
Description: The patients will have their bloods drawn at the Hospital for Special Surgery during their regular, standard of care visit. The laboratory at the Hospital for Special Surgery will then test their bloods to determine the metal ion levels.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood levels drawn
Description: The patients will have their bloods drawn at the Hospital for Special Surgery during their regular, standard of care visit. The laboratory at the Hospital for Special Surgery will then test their bloods to determine the metal ion levels.
Study: NCT01324492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study: NCT03347773

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ReGen 18%
Description: ReGen 18% is a kind of oral nutritional supplement, designed for patients under regular hemodialysis. One can of ReGen 18% contains 237ml, 425 Kcal, 19.1g protein, 22.7g lipid and 37.9g carbohydrate.
Study: NCT03053908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Actigraphy
Description: Recording of sleep/wake cycle and TST by actigraphy to be completed at home by subject over 7 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nocturnal Polysomnograpahy (NPSG)
Description: N1 habituation and N2 data collection
Study: NCT01004484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A probiotic yogurt with inulin
Description: A 4 oz. cup with a probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10\^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10\^7 cfu/g; 5x10\^9 cfu/serving) and Inulin (3gr/serving), once daily.
Study: NCT01580735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: ARQ 197:360 mg bid (CYP2C19 EM) or 240mg bid (CYP2C19 PM)~erlotinib: 150 mg qd
Study: NCT00862225

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadin
Description: Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IG-RD-001 / Ze 339
Description: Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
Study: NCT01004484

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acidified dairy snack
Description: A 4 oz. cup of acidified dairy snack, once daily.
Study: NCT00304954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Daclizumab
Description: Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
Study: NCT04936412

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation brace
Description: Rehabilitation brace

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation brace
Description: Rehabilitation brace
Study: NCT01746628

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy with FloSeal
Description: Evaluation of the effects of intrauterine FloSeal

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hysterectomy with FloSeal
Description: Evaluation of the effects of intrauterine FloSeal
Study: NCT00304954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Infliximab
Description: Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Rapamycin
Description: Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
Study: NCT04304950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evening Group
Description: Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 pm and 11:00 pm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morning Group
Description: Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 am and 11:00 am.
Study: NCT04150783

Intervention type: PROCEDURE
Intervention: Surgical repair for nasal obstruction
Description: Patient reported quality of life questionnaires
Study: NCT01999790

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blepharotomy
Description: upper eyelid surgery by blepharotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior approach
Description: upper eyelid surgery by posterior approach
Study: NCT01889862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMN165 20mg/day
Description: BMN165 20mg/day self-administered daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMN165 40mg/day
Description: BMN165 40mg/day self-administered daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-drug placebo, self-administered daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-drug placebo, self-administered daily
Study: NCT04607967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Oxygen
Description: Study participants are suffering from an acute hypoxemic respiratory distress. They have to be treated with oxygen-therapy that could be administered using a conventional oxygen device (study group CO) or High Flow Nasal Oxygen (study group HNFO). During the first 60 minutes following patients admission, patients will be randomized to one of the two study groups. In both groups, the failure of the treatment will be evaluated by the need for a therapeutic escalation fours hours after the treatment initiation.
Study: NCT02808455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Treatment A)
Description: Four 100-mg capsules of pacritinib administered as a single oral dose
Study: NCT00877266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perineural mepivicaine catheter placed via ultrasound or electrical stimulation
Description: Patients will be randomized to one of two groups: catheter placement via ultrasound or nerve stimulation. Placement of the catheter will be timed by research staff and discomfort level asked after placement of catheter. If the catheter is not placed by the randomized method within 15 minutes, the practitioner my switch to the alternate method. Patients will be called the morning after surgery by research staff to assess discomfort levels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perineural mepivicaine catheter placed via ultrasound or electrical stimulation
Description: Patients will be randomized to one of two groups: catheter placement via ultrasound or nerve stimulation. Placement of the catheter will be timed by research staff and discomfort level asked after placement of catheter. If the catheter is not placed by the randomized method within 15 minutes, the practitioner my switch to the alternate method. Patients will be called the morning after surgery by research staff to assess discomfort levels.
Study: NCT03294278

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ablation plus ICD
Description: Defibrillator, radio-frequency catheter ablation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ablation plus ICD
Description: Defibrillator, radio-frequency catheter ablation
Study: NCT00003070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril maleate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril maleate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril maleate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril maleate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril maleate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril maleate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril maleate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril maleate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT02808455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Treatment A)
Description: Four 100-mg capsules of pacritinib administered as a single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Treatment B)
Description: A single 80-mg oral solution dose of pacritinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Treatment B)
Description: A single 80-mg oral solution dose of pacritinib
Study: NCT00251810

Intervention type: DEVICE
Intervention: Cerebral State Monitor
Description: All patients monitored with BIS and CSM, results hidden for the anesthesiologist.
Study: NCT04950101

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: anal sampling
Description: anal sampling will be performed both in men without HIV and men having HIV in order to see if they have HPV or not

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: anal sampling
Description: anal sampling will be performed both in men without HIV and men having HIV in order to see if they have HPV or not
Study: NCT00003070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT00380068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Oral tablets taken once daily.
Study: NCT04207190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV
Study: NCT00003070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT03474289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: Monotherapy
Study: NCT02787226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine Infiltration
Description: Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine Infiltration
Description: Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Perineural Ropivicaine Infusion
Description: Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Perineural Ropivicaine Infusion
Description: Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine.
Study: NCT05093179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep tissue massage
Description: Administered as a soft tissue mobilization performed by the therapist with fingertips, knuckles, elbows and/or fists on the tissues that manifest symptoms of fascial restrictions. The techniques were performed with individually adjusted force until the change (eg. increased mobility) in the tissue being treated was stated by the therapist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic massage
Description: The subject was lying supine on the table, with a roller placed under the knee joints, the upper limbs along the body. The following sequence of techniques was used in the longitudinal and transverse strands and in the intercostal spaces (excluding the breast in women): effleurage, friction, petrissage, pressures, tapotement and vibrations.
Study: NCT02173626

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Training
Description: Participants enrolled on a first-come, first-serve basis, engaging in three 90-minute in person trainings, weekly online video-module trainings, and weekly teleconference coaching calls. Video-module trainings were available at all times, to be accessed at the participants' convenience. Journals and a guided meditation audio library were also provided.
Study: NCT02924571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate Concentrate (BMAC) + Allograft
Description: Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest. Harvest BMAC System delivers high stem cell concentration to the graft site.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Bone Morphogenetic Protein-2 (BMP)
Description: INFUSE rhBMP-2 Bone Graft used according to its approved FDA labels, both from an anterior approach using titanium cages as well as from a posterior interbody approach using polyetheretherketone (PEEK) cages.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft
Description: Autograft with bone marrow aspirate.
Study: NCT04487145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.
Study: NCT01335464

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching BIBF1120, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: BIBF1120 BID (twice daily)
Study: NCT01674842

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Once daily, Monday - Friday for six weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenously, once weekly for six weeks